Skip to main content

Advertisement

Table 2 Mean values and the range of dosimetric data for the different treatment plans as planned and recalculated using

From: Developing and evaluating stereotactic lung RT trials: what we should know about the influence of inhomogeneity corrections on dose

  CC UD     EPL    
  Planned Planned p-value Recalculated p-value Planned p-value recalculated p-value
D95 [Gy] 60.0 60.0 - 56.9 [42.1–63.4] 0.007 60.0 - 48.0 [34.6–56.1] < 0.001
D99 [Gy] 58.5 [57.6–59.5] 58.8 [57.8–59.8] < 0.001 54.5 [39.6–62.0] < 0.001 58.8 [58.1–59.7] < 0.001 45.9 [32.6–53.7] < 0.001
Disoc [Gy] 74.3 [66.0–84.1] 66.6 [62.5–71.3] < 0.001 72.7 [59.3–79.6] 0.19 67.1 [63.2–72.2] < 0.001 61.7 [47.9–70.1] < 0.001
Dmean [Gy] 66.9 [64.1–71.0] 64.1 [61.6–66.6] < 0.001 65.0 [49.1–71.0] 0.11 64.3 [61.8–66.4] < 0.001 55.2 [39.7–62.1] < 0.001
Dmax [Gy] 75.6 [67.8–87.4] 68.1 [63.0–73.3] < 0.001 73.8 [61.3–81.7] 0.17 68.5 [63.8–76.5] < 0.001 62.9 [48.0–74.2] < 0.001
V100%/VPTV 1.13 [0.98–1.38] 1.09 [0.98–1.25] 0.14 0.98 [0.01–1.45] 0.08 1.09 [1.03–1.22] 0.026 0.27 [0.00–0.71] < 0.001
V50%/VPTV 8.4 [4.5–18.2] 6.3 [4.4–12.6] < 0.001 6.6 [4.9–12.2] 0.006 6.3 [4.1–12.0] < 0.001 4.8 [3.1–6.5] < 0.001
V20 Gy [%] 6.6 [2.9–16.7] 5.6 [2.2–14.2] < 0.001 6.0 [2.3–15.5] 0.017 5.2 [2.1–12.3] < 0.001 4.1 [1.5–10.9] < 0.001
V10 Gy [%] 13.7 [7.3–35.8] 12.1 [5.9–29.9] < 0.001 13.1 [6.1–33.5] 0.038 12.0 [5.5–29.5] < 0.001 10.9 [4.6–27.3] < 0.001
MLD [cGy] 456 [257–941] 396 [203–828] < 0.001 439 [223–905] 0.18 394 [205–738] < 0.001 355 [183–683] < 0.001
  1. full inhomogeneity corrections, and the p-values for the paired-sample t-test comparing the UD and EPL calculated and recalculated plans to the CC plan.